DUBLIN--(

都柏林--(

BUSINESS WIRE

商业热线

)--The

)--The

'Influenza Vaccines Market, Persons Vaccinated, By Segment - Vaccine Type, Indication, Technology, Route of Administration, End-user, Geography, Company Analysis - Global Forecast (2025 - 2032)'

report has been added to

报表已添加到

ResearchAndMarkets.com's

ResearchAndMarkets.com的

offering.

提供。

The global influenza vaccines market is projected to reach US$ 12.16 Billion by 2032, from US$ 7.60 Billion in 2024. According to data published by the World Health Organization (WHO) in 2023, around 3 to 5 million severe influenza cases were recorded, leading to 290,000 to 650,000 deaths across the globe.

到2032年，全球流感疫苗市场预计将从2024年的76亿美元增至121.6亿美元。根据世界卫生组织（WHO）2023年公布的数据，全球约有300万至500万例严重流感病例，导致29万至65万人死亡。

Several worldwide pharmacoeconomic studies have shown that vaccination can prevent about 50% of deaths from influenza-related complications in the elderly. The Centers for Disease Control and Prevention (CDC) recommends routine seasonal influenza vaccination for all individuals 6 months of age and older..

几项全球药物经济学研究表明，接种疫苗可以预防约50%的老年人死于流感相关并发症。疾病控制与预防中心（CDC）建议所有6个月及以上的人常规接种季节性流感疫苗。。

The vast population base together with significantly low vaccination coverage in emerging markets, the introduction of new vaccines, rising government support for immunization and growing awareness of the value of influenza vaccine in preventing disease are the prominent factors that will drive the influenza vaccines market growth.

庞大的人口基础，新兴市场的疫苗接种覆盖率明显较低，新疫苗的推出，政府对免疫接种的支持不断提高，以及人们对流感疫苗在预防疾病中的价值的认识不断提高，这些都是推动流感疫苗市场增长的突出因素。

Moreover, the increasing R&D investments by leading market players, such as Sanofi, CSL Limited, and GSK plc, for expanding manufacturing capabilities and focus on launching new vaccines will propel the market for influenza vaccines over the forecast period..

此外，赛诺菲（Sanofi）、CSL Limited和葛兰素史克（GSK plc）等主要市场参与者为扩大生产能力和专注于推出新疫苗而增加的研发投资，将在预测期内推动流感疫苗市场的发展。。

For instance, in March 2024, Cadila Pharmaceuticals, India launched Cadiflu Tetra Vaccine, an advanced quadrivalent influenza vaccine approved by the DCGI for adults and children. Recently, in June 2024, Moderna, Inc. announced that its Phase 3 trial for mRNA-1083, an investigational combination vaccine targeting influenza and COVID-19, has successfully achieved its primary endpoints, demonstrating a stronger immune response compared to licensed comparator vaccines used in the study..

例如，2024年3月，印度卡迪拉制药公司（Cadila Pharmaceuticals）推出了Cadiflu Tetra疫苗，这是一种由DCGI批准用于成人和儿童的先进四价流感疫苗。最近，在2024年6月，Moderna，Inc.宣布其针对流感和新型冠状病毒19的研究性联合疫苗mRNA-1083的3期试验已成功实现其主要终点，与研究中使用的许可比较疫苗相比，表现出更强的免疫应答。。

Recent Developments

最近的发展

In December 2024, The US Food and Drug Administration has granted Fast Track designation to two Sanofi combination vaccine candidates to prevent influenza and COVID-19 infections in individuals 50 years of age and older.

2024年12月，美国食品和药物管理局批准了两种赛诺菲联合疫苗候选药物的快速通道，以预防50岁及以上人群的流感和新型冠状病毒感染。

In September 2024, Osivax and KM Biologics Co., Ltd., announced a license option agreement granting KM Biologics an exclusive license option to develop, manufacture and commercialize Osivax's broad-spectrum 'universal' influenza vaccine candidates for the Japanese market.

2024年9月，Osivax和KM Biologics Co.，Ltd.宣布了一项许可选择协议，授予KM Biologics独家许可选择权，为日本市场开发、制造和商业化Osivax的广谱“通用”流感候选疫苗。

In July 2024, CSL Seqirus was selected by the Health Emergency Preparedness and Response Authority (HERA), part of the European Commission (EC), to provide 665,000 pre-pandemic vaccine doses for fifteen EU and EEA Member States as well as to the ''Union Civil Protection Mechanism'' (rescEU).

2024年7月，欧洲委员会（EC）的卫生应急准备和响应管理局（HERA）选择了CSL-Seqirus，为15个欧盟和欧洲经济区成员国以及“欧盟公民保护机制”（rescEU）提供665000剂大流行前疫苗。

In October 2023, BioNTech SE and Pfizer Inc. announced positive results from a Phase 1 study of mRNA-based combination vaccine for influenza and COVID-19.

2023年10月，BioNTech SE和辉瑞公司宣布了一项针对流感和新型冠状病毒的基于mRNA的联合疫苗的第一阶段研究的阳性结果。

Influenza Vaccines Market and Forecast Market Segmentation:

流感疫苗市场和预测市场细分：

By Region:

按地区：

Geographically, North America is the largest market for influenza vaccines capturing over 50% share in 2024, owing to rising awareness of influenza viruses, high healthcare expenditure, and increasing research and development activities.

从地理上看，由于对流感病毒的认识不断提高，医疗保健支出居高不下以及研发活动不断增加，北美是2024年流感疫苗的最大市场，份额超过50%。

Europe captured second highest share of the global influenza vaccines market in 2024. In the European region, almost all countries have national and/or regional vaccination policies or strategies for seasonal influenza in place.

2024年，欧洲占据了全球流感疫苗市场第二高的份额。在欧洲地区，几乎所有国家都有针对季节性流感的国家和/或区域疫苗接种政策或策略。

In United Kingdom, the flu vaccine coverage for people aged 65 years and over again remained higher than the target, resulting in four consecutive years of flu vaccine coverage at a standard espoused by the WHO.

在英国，65岁及以上人群的流感疫苗接种率仍然高于目标，导致连续四年的流感疫苗接种率达到世卫组织认可的标准。

In the 2023/2024 season, the vaccine coverage in Denmark among elderly ?65 years was estimated at 79%.

在2023/2024赛季，丹麦的疫苗覆盖率在老年人中？65岁估计为79%。

Asia is expected to be the fastest growing market for influenza vaccines, driven by the increasing population in the Asian countries, growing focus of the governments on enhancing healthcare facilities, rising incidence of seasonal influenza, and rising disposable income.

亚洲预计将成为增长最快的流感疫苗市场，这是由于亚洲国家人口不断增加，政府越来越重视加强医疗设施，季节性流感发病率不断上升，可支配收入不断增加。

Korea ranked highest in influenza vaccination rate in Asia at 311 vaccines per 1,000 people.

韩国是亚洲流感疫苗接种率最高的国家，每1000人接种311种疫苗。

Indonesia has a low rate of influenza vaccination because immunization shots are expensive.

印度尼西亚的流感疫苗接种率很低，因为疫苗接种费用很高。

By Vaccine Type:

按疫苗类型：

Inactivated vaccines held the largest market share of over 90% in 2024, and are anticipated to grow at the fastest rate over the forecast period.

2024年，灭活疫苗拥有超过90%的最大市场份额，预计在预测期内增长最快。

The live attenuated influenza vaccines market is a growing segment within the global vaccine industry, primarily focused on vaccines designed to prevent influenza by using live, but weakened (attenuated), strains of the influenza virus.

减毒活流感疫苗市场是全球疫苗行业中一个不断增长的细分市场，主要集中在通过使用活的但减弱（减毒）的流感病毒株来预防流感的疫苗上。

By Indication:

根据指示：

The quadrivalent vaccines dominated the global influenza vaccines market in 2024, and is expected to grow at the fastest rate over the forecast period.

2024年，四价疫苗主导了全球流感疫苗市场，预计在预测期内将以最快的速度增长。

The market for trivalent influenza vaccines is facing a decline in favor of quadrivalent influenza vaccines. Trivalent vaccines remain crucial in seasonal influenza vaccination programs, especially in areas with limited resources and vaccine access.

三价流感疫苗的市场正面临着四价流感疫苗的下降。三价疫苗在季节性流感疫苗接种计划中仍然至关重要，特别是在资源和疫苗获取有限的地区。

By Technology:

按技术：

Egg-based vaccines accounted for highest share of the global influenza vaccines market in 2024. Egg-based vaccine production has been a longstanding and well-established method in the industry. Several vaccine manufacturers have invested heavily in egg-based infrastructure, making it a widely adopted and reliable production method..

2024年，蛋基疫苗在全球流感疫苗市场中所占份额最高。基于鸡蛋的疫苗生产一直是该行业中一种长期且成熟的方法。几家疫苗制造商在鸡蛋基础设施上投入了大量资金，使其成为一种被广泛采用且可靠的生产方法。。

Cell-based influenza vaccines are an alternative to the traditional egg-based vaccines, offering several advantages in terms of speed, efficiency, and safety.

基于细胞的流感疫苗是传统鸡蛋疫苗的替代品，在速度，效率和安全性方面具有多个优势。

By Route of Administration:

按给药途径：

The injection segment held the largest market share in 2024. Healthcare payers prefer injection over nasal sprays due to better data on safety, efficacy, and cost-effectiveness with decades of use.

2024年，注射部门占据了最大的市场份额。医疗保健付款人更喜欢注射而不是鼻腔喷雾剂，因为经过数十年的使用，安全性，有效性和成本效益的数据更好。

Nasal spray influenza vaccines offer an alternative to injections, providing a non-invasive and needle-free administration option. The increasing adoption of nasal spray or intranasal vaccines at home care settings, ease of self-administration, and ability of nasal spray to induce systemic as well as mucosal immunity drives the segment growth..

鼻喷雾剂流感疫苗提供了注射的替代方案，提供了非侵入性和无针给药选择。在家庭护理环境中越来越多地采用鼻喷雾剂或鼻内疫苗，易于自我管理，以及鼻喷雾剂诱导全身和粘膜免疫的能力推动了该细分市场的增长。。

By End User:

按最终用户：

Hospitals & pharmacies captured largest revenue share of over 50% in 2024. Hospitals & pharmacies are widely accessible to the general population. These healthcare settings benefit from established infrastructure along with the presence of trained healthcare professionals, collaboration with public health campaigns, and insurance coverage..

。医院和药店为普通人群提供了广泛的服务。这些医疗保健机构受益于已建立的基础设施，以及训练有素的医疗保健专业人员的存在，与公共卫生运动的合作以及保险范围。。

Government & institutional supply is expected to be the fastest-growing segment over the coming years. Ongoing vaccination and immunization programs and the inclusion of influenza vaccines in vaccination programs worldwide are responsible for high growth of this segment.

预计政府和机构供应将成为未来几年增长最快的部分。正在进行的疫苗接种和免疫接种计划以及将流感疫苗纳入全球疫苗接种计划是这一部分高增长的原因。

Global Influenza Vaccines Market Company Analysis

全球流感疫苗市场公司分析

GSK's influenza vaccines sales declined in 2024, driven by competitive pressure and volume phasing in the US and lower demand across other regions.

2024年，葛兰素史克的流感疫苗销售额下降，这是由于竞争压力和美国的数量逐步减少以及其他地区的需求下降所致。

In 2023, Sanofi net sales of influenza vaccines declined by 10%, due to a slight reduction in vaccine uptake and increased competition in the United States.

2023年，由于疫苗摄取量略有减少和美国竞争加剧，赛诺菲流感疫苗的净销售额下降了10%。

In December 2024, The US Food and Drug Administration has granted Fast Track designation to two Sanofi combination vaccine candidates to prevent influenza and COVID-19 infections in individuals 50 years of age and older.

2024年12月，美国食品和药物管理局批准了两种赛诺菲联合疫苗候选药物的快速通道，以预防50岁及以上人群的流感和新型冠状病毒感染。

Influenza Vaccines Market - Key Company Analysis

流感疫苗市场-主要公司分析

GlaxoSmithKline

葛兰素史克

Sanofi

赛诺菲

CSL Seqirus

AstraZeneca

阿斯利康

Gamma Vaccines

γ疫苗

Hualan Bioengineering Co.

华兰生物工程有限公司。

Viatris

维亚特里斯

BioDiem

生物Diem

Shanghai Institute of Biological Products Co.

上海生物制品研究所有限公司。

Influenza Vaccines Market - Emerging Players Profile

流感疫苗市场-新兴参与者简介

Novavax

诺瓦克斯

Moderna

现代

Pneumagen

气动装置

Daiichi-Sankyo

大一三

FluGen

FluGen 的

Imutex

Imutex 的

EpiVax

Epivax

Versatope Therapeutics

Versatope治疗学

BIKEN Co

BIKEN 公司

Sinovac Biotech

北京科兴生物

Emergent BioSolutions

新兴生物解决方案

Osivax

奥西瓦克斯

Gylden Pharma

吉尔登制药

Vir Biotechnology

Vir生物技术

Key Topics Covered:

涵盖的关键主题：

1. Executive Summary

1、执行摘要

2. Global Influenza Vaccines Market and Forecast (2016 - 2032)

2、全球流感疫苗市场及预测（2016-2032）

2.1 Global Influenza Vaccines Market and Forecast

2.1全球流感疫苗市场及预测

2.2 Global Number of Persons Vaccinated with Influenza Vaccines and Forecast

2.2全球接种流感疫苗的人数和预测

3. Global Influenza Vaccines Market Share and Forecast (2016 - 2032)

3、全球流感疫苗市场份额及预测（2016-2032）

3.1 Influenza Vaccines Market Share and Forecast - Regional Analysis

3.1流感疫苗市场份额和预测-区域分析

3.2 Persons Vaccinated with Influenza Vaccines Share and Forecast - Regional Analysis

3.2接种流感疫苗的人群比例和预测-区域分析

3.3 By Vaccine Type Global Influenza Vaccines Market Share and Forecast

3.3按疫苗类型划分的全球流感疫苗市场份额和预测

3.4 By Indication Global Influenza Vaccines Market Share and Forecast

3.4根据指示全球流感疫苗市场份额和预测

3.5 By Technology Global Influenza Vaccines Market Share and Forecast

3.5按技术划分的全球流感疫苗市场份额和预测

3.6 By Route of Administration Global Influenza Vaccines Market Share and Forecast

3.6按给药途径分列全球流感疫苗市场份额和预测

3.7 By End User Global Influenza Vaccines Market Share and Forecast

3.7按最终用户分列的全球流感疫苗市场份额和预测

4. Influenza Vaccines Market, Persons Vaccinated and Forecast - By Region (2016 - 2032)

4、流感疫苗市场、接种人数和预测-按地区（2016-2032年）

5. Influenza Vaccines Market, Persons Vaccinated and Forecast - Country Wise Distribution (2016 - 2032)

5、流感疫苗市场、接种人数和预测-国别分布（2016-2032）

6. By Vaccine Type - Global Influenza Vaccines Market and Forecast (2016 - 2032)

6.按疫苗类型-全球流感疫苗市场和预测（2016-2032）

6.1 Inactivated

6.1灭活

6.2 Live Attenuated

6.2活衰减

7. By Indication - Global Influenza Vaccines Market and Forecast (2016 - 2032)

7.根据适应症-全球流感疫苗市场和预测（2016-2032）

7.1 Quadrivalent

7.1四价

7.2 Trivalent

7.2三价

8. By Technology - Global Influenza Vaccines Market and Forecast (2016 - 2032)

8.技术-全球流感疫苗市场和预测（2016-2032）

8.1 Egg-based

8.1蛋基

8.2 Cell-based

8.2基于细胞

9. By Route of Administration - Global Influenza Vaccines Market and Forecast (2016 - 2032)

9.按给药途径-全球流感疫苗市场和预测（2016-2032）

9.1 Injection

9.1注射

9.2 Nasal Spray

9.2鼻喷雾剂

10. By End User - Global Influenza Vaccines Market and Forecast (2016 - 2032)

10.按最终用户-全球流感疫苗市场和预测（2016-2032）

10.1 Hospitals & Pharmacies

10.1医院和药房

10.2 Government & Institutional Supply

10.3 Others

10.3其他

11. Global Influenza Vaccines Market - Key Company Analysis

11、全球流感疫苗市场——主要公司分析

11.1 GlaxoSmithKline (GSK)

11.1葛兰素史克（GSK）

11.2 Sanofi

11.2赛诺菲

11.3 CSL Seqirus

11.3 CSL序列病毒

11.4 AstraZeneca

11.4阿斯利康

11.5 Gamma Vaccines

11.5γ疫苗

11.6 Hualan Bioengineering Co.

11.6华兰生物工程有限公司。

11.7 Viatris

11.7维亚特里斯

11.8 BioDiem

11.8 生物Diem

11.9 Shanghai Institute of Biological Products Co.

11.9上海生物制品研究所有限公司。

12. Global Influenza Vaccines Market - Emerging Players Profile

全球流感疫苗市场-新兴参与者简介

12.1 Novavax

12.1诺瓦瓦

12.2 Moderna

12.2 现代

12.3 Pneumagen

12.3分

12.4 Daiichi-Sankyo

12.4第一三共

12.5 FluGen

12.5 飞行

12.6 Imutex

12.6 Imutex

12.7 EpiVax

12.7埃皮瓦

12.8 Versatope Therapeutics

12.8 Versatope治疗学

12.9 BIKEN Co.

12.9比肯公司。

12.10 Sinovac Biotech

12.10 生物科技

12.11 Emergent BioSolutions

12.11 新兴生物解决方案

12.12 Osivax

12.12 奥西瓦克斯

12.13 Gylden Pharma Limited (Previously Emergex Vaccines)

12.13 Gylden Pharma Limited（之前的Emergex疫苗）

12.14 Vir Biotechnology, Inc.

12.14 Vir生物技术公司。

13. Global Influenza Vaccines Market Major Deals

13、全球流感疫苗市场重大交易

13.1 Mergers and Acquisitions

13.2 Licensing Agreements

13.2许可协议

13.3 Collaboration Agreements

13.3合作协议

14. Global Influenza Vaccines Market Recent Developments

全球流感疫苗市场最新发展

15. Global Influenza Vaccines Market Driving Factors

15、全球流感疫苗市场驱动因素

16. Global Influenza Vaccines Market Challenges

16、全球流感疫苗市场挑战

For more information about this report visit

有关此报告的更多信息，请访问

https://www.researchandmarkets.com/r/6mai4y

https://www.researchandmarkets.com/r/6mai4y

About ResearchAndMarkets.com

关于ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

ResearchAndMarkets.com是全球领先的国际市场研究报告和市场数据来源。我们为您提供有关国际和地区市场、关键行业、顶尖公司、新产品和最新趋势的最新数据。